PXD031455 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line |
Description | Azacytidine (AzaC) and decitabine (AzadC) are cytosine analogs that covalently trap DNA methyltransferases, which place the important epigenetic mark 5-methyl-2’-deoxycytidine by methylating 2’-deoxycytidine (dC) at the C5 position. AzaC and AzadC are used in the clinic as antimetabolites to treat myelodysplastic syndrome and acute myeloid leukemia and are explored against other types of cancer. Although their principal mechanism of action is known, the downstream effects of AzaC and AzadC treatment are not well understood and the cellular prerequisites that determine sensitivity towards AzaC and AzadC remain elusive. Here, we investigated the effects and phenotype of AzaC and AzadC exposure on the acute myeloid leukemia cell line MOLM-13. We found that while AzaC and AzadC share many effects on the cellular level, including decreased global DNA methylation, increased formation of DNA double strand breaks, transcriptional downregulation of important oncogenes and similar changes on the proteome level, AzaC failed in contrast to AzadC to induce apoptosis in MOLM-13. The only cellular marker that correlated with this clear phenotypical outcome was the level of hydroxy-methyl-dC, an additional epigenetic mark that is placed by TET enzymes and repressed in cancer cells. Whereas AzadC increased hmdC substantially in MOLM-13, AzaC treatment did not result in any increase at all. This suggests that hmdC levels in cancer cells should be monitored as a response towards AzaC and AzadC and considered as a biomarker to judge whether AzaC or AzadC lead to cell death in leukemic cells. |
HostingRepository | PRIDE |
AnnounceDate | 2022-09-19 |
AnnouncementXML | Submission_2022-09-19_06:59:35.007.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Franziska Traube |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | carbamoylated residue; phosphorylated residue; monohydroxylated residue |
Instrument | Orbitrap Eclipse |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2022-02-05 13:34:18 | ID requested | |
⏵ 1 | 2022-09-19 06:59:36 | announced | |
Publication List
Aumer T, Gremmelmaier CB, Runtsch LS, Pforr JC, Ye, ş, ilta, ç GN, Kaiser S, Traube FR, Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line. Clin Epigenetics, 14(1):113(2022) [pubmed] |
Keyword List
submitter keyword: Cancer, epigenetics, DNA hypomethylation, DNA damage, 5-Aza-Cytidine, 5-Aza-2'-deoxycytidine |
Contact List
Franziska Traube |
contact affiliation | Institute for Chemical Epigenetics Department of Chemistry LMU München Würmtalstr. 201 81375 Munich Germany |
contact email | franziska.traube@cup.lmu.de |
lab head | |
Franziska Traube |
contact affiliation | LMU Munich - Department Chemie |
contact email | franziska.traube@cup.lmu.de |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/09/PXD031455 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD031455
- Label: PRIDE project
- Name: Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line